StockData
Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd (KZIA) KPIs and segments

KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 17, 2026Score 1/30
$5.49+0.18 (+3.39%)

Close on Nov 18, 2026Market cap $8.89MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Kazia Therapeutics's business

Kazia Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Kazia Therapeutics's fiscal year ends June 30 — FY2025 = CY2025 (calendar year).

Periods
Add to chartMetric
FY2025
FY2024
FY2023
FY2022
FY2021
Sale of paxalisib(A$M)
0.040.0100
Licensing revenue(A$M)
02.300015.2
Israel(A$M)
0.0400
KR(A$M)
02.3100
Earlier reporting (last reported 2023)3

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2025-11-07.

See a number that looks wrong?